Chao Q Lin

US Patent:

7438920, Oct 21, 2008

Filed:

Apr 30, 1999

Appl. No.:

09/303216

Inventors:

Joseph L. Kim - Natick MA, US
Kurt Morgenstern - Derry NH, US
Paul Caron - Malden MA, US
Chao Lin - Brookline MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 39/29
A61K 38/43
G01N 33/53
C12N 9/00

US Classification:

4242281, 435 71, 435183, 514 2, 514 12

Abstract:

The invention relates to the X-ray crystal structure of the hepatitis C virus helicase domain. More specifically, the invention relates to crystallized complexes of HCV helicase and an oligonucleotide, to crystallizable compositions of HCV helicase and an oligonucleotide and to methods of crystallizing an HCV helicase-oligonucleotide complex. The invention further relates to a computer programmed with the structure coordinates of the HCV helicase oligonucleotide binding pocket or the HCV helicase nucleotide triphosphate pocket wherein said computer is capable of displaying a three-dimensional representation of that binding pocket.

US Patent:

7494660, Feb 24, 2009

Filed:

Oct 27, 2004

Appl. No.:

10/974558

Inventors:

Chao Lin - Winchester MA, US
Kai Lin - Waltham MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C12N 7/00
C07H 21/04

US Classification:

4242181, 536 231

Abstract:

The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

US Patent:

7705138, Apr 27, 2010

Filed:

Nov 13, 2006

Appl. No.:

11/599162

Inventors:

Chao Lin - Winchester MA, US
Tara Kieffer - Brookline MA, US
Christoph Sarrazin - Hamburg, DE
Ann Kwong - Cambridge MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C12N 15/57
C12N 15/51
C12N 15/74
C12N 15/79
C12N 9/50
C12P 19/34

US Classification:

536 232, 435 691, 435 9121, 435219, 4352523, 4353201, 536 231, 536 2372

Abstract:

The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

US Patent:

7884199, Feb 8, 2011

Filed:

Nov 17, 2008

Appl. No.:

12/272425

Inventors:

Chao Lin - Winchester MA, US
Kai Lin - Waltham MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C07H 23/00
C12N 7/00
C12Q 1/70

US Classification:

536 2371, 4353201, 435 691, 4352351, 435 6

Abstract:

The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment.

US Patent:

8258116, Sep 4, 2012

Filed:

May 5, 2008

Appl. No.:

12/598802

Inventors:

Ann Kwong - Cambridge MA, US
Nagraj Mani - Natick MA, US
Yi Zhou - Lexington MA, US
Chao Lin - Winchester MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A01N 43/04
A61K 31/70

US Classification:

514 49, 514 43, 514 50, 514 51

Abstract:

The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.

US Patent:

8425850, Apr 23, 2013

Filed:

Dec 8, 2010

Appl. No.:

12/962978

Inventors:

Chao P. Lin - Columbus OH, US
Darren C. Hanby - Frazeysburg OH, US
Jeffery L. Hofacre - Columbus OH, US
Thomas E. McCartney - Westerville OH, US
James Silk - Chillicothe OH, US

Assignee:

American Electric Power Company, Inc. - Columbus OH

International Classification:

B01D 46/00
B01J 19/00

US Classification:

422176, 55300, 55307, 553851, 422616

Abstract:

Embodiments describe an arrangement for reducing the amount of LPA that reaches a NOx reducing apparatus such as a SCR system. The arrangement includes deflection elements, screens, means for dislodging any LPA that might become lodged in the screens, an aperture for removing the ash through, hoppers or collection means and an ash conveyance system. The arrangement is positioned in a region of ductwork with a reduced gas flow such as the SCR reactor. The screens are positioned relative to one another to direct the LPA downward toward an aperture for removal. In one embodiment the positioning of the screens creates a half-trough or inverted pyramid appearance when placed next to a vertical wall in the flue gas ductwork or the SCR reactor. The low point of the trough is in communication with the aperture allowing the LPA to exit the flue ductwork.

US Patent:

8501450, Aug 6, 2013

Filed:

Mar 5, 2010

Appl. No.:

12/718340

Inventors:

Chao Lin - Winchester MA, US
Tara Kieffer - Brookline MA, US
Christoph Sarrazin - Saarland, DE
Ann Kwong - Cambridge MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C12N 9/50
C12N 15/51
C12N 15/57
C12N 15/74
C12N 15/79
C12P 19/34

US Classification:

435219, 4352523, 4353201, 536 232, 536 2372

Abstract:

The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.

US Patent:

20020042046, Apr 11, 2002

Filed:

Sep 14, 2001

Appl. No.:

09/952975

Inventors:

Joseph Kim - Natick MA, US
Kurt Morgenstern - Derry NH, US
Chao Lin - Cambridge MA, US
Ted Fox - Maynard MA, US
John Thomson - Belmont MA, US

Assignee:

Vertex Pharmaceuticals, Incorporated

International Classification:

C12Q001/70
C12N009/50
C12N007/00

US Classification:

435/005000, 435/219000, 435/235100

Abstract:

The present invention relates to compositions and crystals of a hepatitis C virus protease in complex with its viral cofactor. This invention also relates to methods of using the structure coordinates of hepatitis C virus protease in complex with a synthetic NS4A to solve the structure of similar or homologous proteins or protein complexes.